Literature DB >> 27356836

Outpatient Terlipressin Infusion for the Treatment of Refractory Ascites.

Paul J Gow1,2, Zaid S Ardalan1, Abhinav Vasudevan1, Adam G Testro1,2, Bei Ye1, Peter W Angus1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27356836     DOI： 10.1038/ajg.2016.168

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  3 in total

1.  The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.

Authors:  Basilio Fimiani; Domenico Della Guardia; Claudio Puoti; Giuseppe D'Adamo; Olimpia Cioffi; Anna Pagano; Maria Rosaria Tagliamonte; Antonio Izzi
Journal:  Eur J Intern Med       Date:  2011-08-02       Impact factor: 4.487

2.  Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients.

Authors:  S Møller; E F Hansen; U Becker; K Brinch; J H Henriksen; F Bendtsen
Journal:  Liver       Date:  2000-02

3.  Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects.

Authors:  Aleksander Krag; Flemming Bendtsen; Erling Bjerregaard Pedersen; Niels-Henrik Holstein-Rathlou; Søren Møller
Journal:  Am J Physiol Renal Physiol       Date:  2008-08-27
  3 in total
  6 in total

Review 1.  Management of ascites and hepatorenal syndrome.

Authors:  Salvatore Piano; Marta Tonon; Paolo Angeli
Journal:  Hepatol Int       Date:  2017-08-23       Impact factor: 6.047

2.  Advances in the Management of Renal Dysfunction in Patients With Cirrhosis.

Authors:  Nathalie A Pena Polanco; Paul Martin; Andres F Carrion
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-05

Review 3.  Management of Portal Hypertension.

Authors:  Anand V Kulkarni; Atoosa Rabiee; Arpan Mohanty
Journal:  J Clin Exp Hepatol       Date:  2022-03-21

4.  Practice guidance for the use of terlipressin for liver cirrhosis-related complications.

Authors:  Xingshun Qi; Zhaohui Bai; Qiang Zhu; Gang Cheng; Yu Chen; Xiaowei Dang; Huiguo Ding; Juqiang Han; Lei Han; Yingli He; Fanpu Ji; Hongxu Jin; Bimin Li; Hongyu Li; Yiling Li; Zhiwei Li; Bang Liu; Fuquan Liu; Lei Liu; Su Lin; Dapeng Ma; Fanping Meng; Ruizhao Qi; Tianshu Ren; Lichun Shao; Shanhong Tang; Yufu Tang; Yue Teng; Chunhui Wang; Ran Wang; Yunhai Wu; Xiangbo Xu; Ling Yang; Jinqiu Yuan; Shanshan Yuan; Yida Yang; Qingchun Zhao; Wei Zhang; Yongping Yang; Xiaozhong Guo; Weifen Xie
Journal:  Therap Adv Gastroenterol       Date:  2022-05-18       Impact factor: 4.802

5.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

6.  Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.

Authors:  Zhaohui Bai; Yang An; Xiaozhong Guo; Rolf Teschke; Nahum Méndez-Sánchez; Hongyu Li; Xingshun Qi
Journal:  Can J Gastroenterol Hepatol       Date:  2020-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.